These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 38506539)

  • 21. [MRI of the prostate].
    Nörenberg D; Solyanik O; Schlenker B; Magistro G; Ertl-Wagner B; Clevert DA; Stief C; Reiser MF; D'Anastasi M
    Urologe A; 2017 May; 56(5):665-677. PubMed ID: 28424829
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Bi- or multiparametric MRI in a sequential screening program for prostate cancer with PSA followed by MRI? Results from the Göteborg prostate cancer screening 2 trial.
    Wallström J; Geterud K; Kohestani K; Maier SE; Månsson M; Pihl CG; Socratous A; Arnsrud Godtman R; Hellström M; Hugosson J
    Eur Radiol; 2021 Nov; 31(11):8692-8702. PubMed ID: 33890152
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Cost-effectiveness analysis of prostate cancer screening and MRI.
    Takahashi T
    World J Urol; 2024 Apr; 42(1):212. PubMed ID: 38578452
    [No Abstract]   [Full Text] [Related]  

  • 24. Integration of multiparametric MRI into active surveillance of prostate cancer.
    Holtz JN; Tay KJ; Polascik TJ; Gupta RT
    Future Oncol; 2016 Nov; 12(21):2513-2529. PubMed ID: 27322161
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Future of screening for prostate cancer.
    Dahm P
    BMJ; 2017 Sep; 358():j4200. PubMed ID: 28928226
    [No Abstract]   [Full Text] [Related]  

  • 26. Implementation of a 5-Minute Magnetic Resonance Imaging Screening Protocol for Prostate Cancer in Men With Elevated Prostate-Specific Antigen Before Biopsy.
    Weiss J; Martirosian P; Notohamiprodjo M; Kaufmann S; Othman AE; Grosse U; Nikolaou K; Gatidis S
    Invest Radiol; 2018 Mar; 53(3):186-190. PubMed ID: 29077588
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Re: Prostate Cancer Screening Using a Combination of Risk-prediction, MRI, and Targeted Prostate Biopsies (STHLM3-MRI): A Prospective, Population-based, Randomised, Open-label, Non-inferiority Trial.
    Raslan M; Mercader C; Lamb AD
    Eur Urol; 2022 May; 81(5):543-544. PubMed ID: 35105477
    [No Abstract]   [Full Text] [Related]  

  • 28. Update from the ReIMAGINE Prostate Cancer Screening Study NCT04063566: Inviting Men for Prostate Cancer Screening Using Magnetic Resonance Imaging.
    Marsden T; McCartan N; Hadley J; Tuck S; Brown L; Haire AJ; Moss CL; Green S; Van Hemelrijck M; Coolen T; Santaolalla A; Isaac E; Brembilla G; Kopcke D; Giganti F; Sidhu H; Punwani S; Emberton M; Moore CM;
    Eur Urol Focus; 2021 May; 7(3):503-505. PubMed ID: 33896710
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Biomarker vs MRI-Enhanced Strategies for Prostate Cancer Screening: The STHLM3-MRI Randomized Clinical Trial.
    Björnebo L; Discacciati A; Falagario U; Vigneswaran HT; Jäderling F; Grönberg H; Eklund M; Nordström T; Lantz A
    JAMA Netw Open; 2024 Apr; 7(4):e247131. PubMed ID: 38648061
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Prostate cancer screening using a combination of risk-prediction, MRI, and targeted prostate biopsies (STHLM3-MRI): a prospective, population-based, randomised, open-label, non-inferiority trial.
    Nordström T; Discacciati A; Bergman M; Clements M; Aly M; Annerstedt M; Glaessgen A; Carlsson S; Jäderling F; Eklund M; Grönberg H;
    Lancet Oncol; 2021 Sep; 22(9):1240-1249. PubMed ID: 34391509
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Benefit, Harm, and Cost-effectiveness Associated With Magnetic Resonance Imaging Before Biopsy in Age-based and Risk-stratified Screening for Prostate Cancer.
    Callender T; Emberton M; Morris S; Pharoah PDP; Pashayan N
    JAMA Netw Open; 2021 Mar; 4(3):e2037657. PubMed ID: 33704474
    [TBL] [Abstract][Full Text] [Related]  

  • 32. MRI as a screening tool for prostate cancer: current evidence and future challenges.
    Würnschimmel C; Chandrasekar T; Hahn L; Esen T; Shariat SF; Tilki D
    World J Urol; 2023 Apr; 41(4):921-928. PubMed ID: 35226140
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Prostate cancer - diagnostics and screening].
    Arnsrud Godtman R; Bratt O; Nordström T; Wallström J; Hugosson J
    Lakartidningen; 2024 Apr; 121():. PubMed ID: 38647107
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Magnetic resonance imaging in the early detection of prostate cancer and review of the literature on magnetic resonance imaging-stratified clinical pathways.
    Shah TT; To WKL; Ahmed HU
    Expert Rev Anticancer Ther; 2017 Dec; 17(12):1159-1168. PubMed ID: 28933973
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Role of Magnetic Resonance Imaging in Prostate Cancer Screening: A Pilot Study Within the Göteborg Randomised Screening Trial.
    Grenabo Bergdahl A; Wilderäng U; Aus G; Carlsson S; Damber JE; Frånlund M; Geterud K; Khatami A; Socratous A; Stranne J; Hellström M; Hugosson J
    Eur Urol; 2016 Oct; 70(4):566-573. PubMed ID: 26724840
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Prostate Cancer Screening with Magnetic Resonance Imaging: Results from the Second Round of the Göteborg Prostate Cancer Screening 2 Trial.
    Wallström J; Geterud K; Kohestani K; Maier SE; Pihl CG; Socratous A; Stranne J; Arnsrud-Godtman R; Månsson M; Hellström M; Hugosson J
    Eur Urol Oncol; 2022 Feb; 5(1):54-60. PubMed ID: 34580053
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The GÖTEBORG prostate cancer screening 2 trial: a prospective, randomised, population-based prostate cancer screening trial with prostate-specific antigen testing followed by magnetic resonance imaging of the prostate.
    Kohestani K; Månsson M; Arnsrud Godtman R; Stranne J; Wallström J; Carlsson S; Hellström M; Hugosson J
    Scand J Urol; 2021 Apr; 55(2):116-124. PubMed ID: 33612068
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Imaging Characteristics of Prostate Cancer Patients Who Discontinued Active Surveillance on 3-T Multiparametric Prostate MRI.
    Habibian DJ; Liu CC; Dao A; Kosinski KE; Katz AE
    AJR Am J Roentgenol; 2017 Mar; 208(3):564-569. PubMed ID: 28075651
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Prospective Validation Study of a Novel Integrated Pathway Based on Clinical Features, Magnetic Resonance Imaging Biomarkers, and MicroRNAs for Early Detection of Prostate Cancer.
    Pecoraro M; Catanzaro G; Conte F; Besharat ZM; Messina E; Laschena L; Trocchianesi S; Splendiani E; Sciarra A; Catalano C; Paci P; Ferretti E; Panebianco V
    Eur Urol Oncol; 2024 Feb; 7(1):73-82. PubMed ID: 37270379
    [TBL] [Abstract][Full Text] [Related]  

  • 40. MRI in early detection of prostate cancer.
    Giganti F; Moore CM
    Curr Opin Urol; 2019 Nov; 29(6):563-568. PubMed ID: 31436569
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.